Study of prednisolone and rituximab in nephrotic syndrome based on novel nanomaterials

Abstract

In the search for a more reasonable yet effective treatment method, this study explores the application of nanometer magnetic particles and prednisolone combined with rituximab in children with nephrotic syndrome (NS). According to the diagnostic criteria of children with hormone sensitivity and frequent recurrence of primary NS from the nephrology group of the Chinese Academy of Pediatrics, 40 children with NS diagnosed in our hospital from January 2018 to October 2019 were selected. Nanomagnetic α-Fe2O3 particles were prepared by chemical reaction synthesis. Before and after treatment, urine protein, oral hormone dosage, changes in peripheral blood CD19 + B lymphocyte levels, changes in plasma immunoglobulin levels, and patient general improvement were observed, along with the recurrence of renal disease after treatment. Immunoglobulin was measured by the immunoturbidimetric method, and the endpoint of the follow-up was the first relapse after administration. This study shows that the use of nanomagnetic particles and prednisolone in combination with rituximab in the treatment of pediatric NS has a significant effect, improving the renal function indicators of children and effectively controlling the condition of children while maintaining a higher level of safety.